盐酸曲美他嗪对老年心衰患者血浆脑钠肽及6 min步行试验的影响

摘要

Objective:To observe influence of trimetazidine on cardiac function in patients With chronic heart failure (CHF).Methods:According to number table method,a total of 70 CHF patients accorded With inclusion standards Were randomly and equally divided into trimetazidine group and routine treatment group.According to patient's condition,routine treatment group received digitalis,diuretics,angiotensin converting enzyme inhibitors etc CHF routine freatment.Trimetazidine group additionally received trimetazidine based on routine treatment.The treat-ment period Was four Weeks.Plasma brain natriuretic peptide (BNP)level Was measured and patients received 6min Walking test (6MWT)before and after treatment.Results:Compared With before treatment,there Was significant decrease in plasma BNP level in tWo groups after treatment (P<0.01),compared With routine treatment group, there Was significant increase in decreasing amplitude of BNP level [(655.89±135.61)pg/ml vs.(715.60±181.22) pg/ml,P<0.05]in trimetazidine group;compared With before treatment,there Was significant increase in 6min Walking distance (6MWD)in tWo groups after treatment (P<0.01),compared With routine treatment group,there Was significant increase in increasing amplitude of 6MWD [(181.46±51.16)m vs.(226.06±65.18)m,P<0.01] in trimetazidine group.Conclusion:Treatment trimetazidine can significantly reduce plasma brain natriuretic peptide level and improve heart function based on routine treatment in patients With heart failure.%目的：观察曲美他嗪对慢性充血性心力衰竭（CHF）患者心功能的影响。方法：70例符合入选标准的 CHF患者按数字表法被随机均分为曲美他嗪组和常规治疗组，各35例。常规治疗组根据病情给予洋地黄、利尿剂、血管紧张素转化酶抑制剂等治疗，曲美他嗪组在常规治疗组基础上加用曲美他嗪，疗程4周，分别于治疗前后检测患者血浆脑钠肽（BNP）水平，并对患者进行6 min步行试验（6 MWT）。结果：两组患者治疗后血浆 BNP水平均较治疗前明显降低（P＜0.01），且曲美他嗪组降低幅度较常规治疗组降低更显著[（715.60±181.22）pg/ml 比（655.89±135.61）pg/ml，P＜0.05]；两组患者治疗后6min步行距离均较治疗前显著增加（P＜0.01），且曲美他嗪组增加幅度较常规治疗组更显著[（226.06±65.18）m比（181.46±51.16）m，P＜0.01]。结论：曲美他嗪在常规治疗基础上能明显降低心衰患者血浆脑钠肽水平，增强运动能力。